MLSSHealthcare · Medical Instruments & Supplies

MLSS Stock Forecast: Milestone Scientific, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$0.35

−0.57% on the day

The 2 Wall Street analysts covering Milestone Scientific, Inc. hold a median 12-month price target of $1.25 — +259.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 10 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap

$31.7M

Ticker Nerd rank

87 / 100

Median analyst target

$1.25

Analysts covering

Revenue$2.8M+22.3% y/y

Operating income−$1.1M

Net income−$1.1M

Free cash flow−$589K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−3.3%

−20.9%

YTD

+28.9%

−33.1%

From 52W high

−36.7%

From 52W low

+39.2%

$0.25

$0.55

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MLSS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Milestone Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Oct 2026

87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Growth

Size

Issuance

Quality

Revisions

Volatility

Value

Momentum

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (43): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MLSS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLSS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $1.00Median $1.25High $1.50

The green dot is the last close — the median target sits +259.2% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
20 Nov 2025	Benchmark	Maintains	Speculative Buy	—
20 Nov 2024	Benchmark	Reiterates	Speculative Buy	—
10 Oct 2024	Benchmark	Initiates	Speculative Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLSS appears on the weeks it earns a place.

Performance

MLSS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Milestone Scientific, Inc. returned −33.1% against +20.4% for the S&P 500, dividends included.

MLSS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLSS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Milestone Scientific, Inc. (MLSS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −5.0×
Price / sales: 3.3×
Price / book: 8.9×
EV / EBITDA: −7.3×

Growth & margins

Revenue growth (YoY): 22.3%
Earnings growth (YoY): 22.3%
Gross margin: 67.2%
Operating margin: −37.4%
Net margin: −44.0%

Returns & dividend

Return on equity: −121.7%
Return on assets: −31.3%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Milestone Scientific, Inc. (MLSS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Milestone Scientific, Inc. has a market value of $31.7M and an enterprise value of $29.4M.
Revenue in the twelve months to 30 June 2026: $9.4M. The latest quarter grew 22.3% year on year.
Net income over the same four quarters: −$4.1M, a −44.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$658K.
Shares outstanding: 88.8M.
Trailing P/E: −5.0×; forward P/E: −9.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Milestone Scientific, Inc. employs 15 people — $628K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

MLSS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
MLSSMilestone Scientific, Inc.	$31.7M	87
HBIOHarvard Bioscience, Inc.	$36.8M	99
NEPHNephros, Inc.	$37.5M	93
RVPRetractable Technologies, Inc.	$19.9M	62
POCIPrecision Optics Corp., Inc.	$50.1M	41
BNGOBionano Genomics, Inc.	$16.9M	77
FEMYFemasys, Inc.	$16.8M	47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Milestone Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MLSS news & analysis

Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business

GlobeNewsWire · 29 Sept 2026positive

Milestone Scientific highlighted progress in building a scalable growth platform for its CompuFlo® medical business, noting momentum driven by expanding physician adoption, improved reimbursement access, broader commercial coverage, and growing clinical evidence.

Why it matters — An MLSS watcher would care because growing adoption, reimbursement access, coverage, and clinical validation of CompuFlo signal the company's advancing commercial traction.

Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor

GlobeNewsWire · 16 Sept 2026positive

Milestone Scientific announced that Pain and Spine Specialists and Dr. Sudhir Rao, M.D., will serve as a CompuFlo development partner and advisor. The announcement was made in a GlobeNewsWire press release from the company's Roseland, New Jersey headquarters.

Why it matters — MLSS watchers would care because partnering with a medical specialist as a development advisor could lend clinical credibility and advance the CompuFlo technology's adoption in pain and spine practices.

Milestone Scientific Inc. (MLSS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Milestone Scientific Inc. held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational performance for the second quarter of fiscal 2026.

Why it matters — The earnings call transcript provides MLSS shareholders and watchers with management's official commentary on second-quarter results, business developments, and forward-looking outlook.

Milestone Scientific Reports Financial Results for Second Quarter 2026

GlobeNewsWire · 14 Aug 2026positive

Milestone Scientific provided a business update and announced financial results for the three and six months ended June 30, 2026, reporting that Medical Segment revenue grew 231% year-over-year. The company also entered a strategic distribution agreement to expand CompuFlo access across VA and Department of Defense health systems and reaffirmed its 2026 outlook for double-digit revenue growth, including significant growth in CompuFlo sales.

Why it matters — MLSS watchers would care because the strong reported revenue growth, the new distribution agreement expanding into VA and Department of Defense health systems, and the reaffirmed double-digit growth outlook indicate meaningful progress and commercial expansion for the company's CompuFlo technology.

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

GlobeNewsWire · 6 Aug 2026neutral

Milestone Scientific announced it will host a conference call on Friday, August 14, 2026, at 8:30 AM Eastern Time to discuss its financial results for the second quarter ended June 30, 2026, along with corporate progress and other developments.

Why it matters — The call provides investors and followers with the company's latest quarterly financial performance and an update on its corporate outlook.

FAQ

Frequently asked questions about MLSS stock

What is the MLSS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Milestone Scientific, Inc. have a median 12-month price target of $1.25, with estimates ranging from $1 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLSS stock a buy right now?

Of the 2 analysts covering Milestone Scientific, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Milestone Scientific, Inc. 87 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLSS?

As at 10 Oct 2026, Milestone Scientific, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will MLSS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +259.2% from the last close, and Ticker Nerd's factor model ranks Milestone Scientific, Inc. 87 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLSS stock forecast for 2030?

No analyst covering Milestone Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLSS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1.5 over the next 12 months.

How has MLSS stock performed over the past year?

Milestone Scientific, Inc. returned -33.1% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Milestone Scientific, Inc. do?

Milestone Scientific Inc. is a biomedical technology company focused on developing and commercializing computer-controlled injection systems for medical and dental use.

What is the latest news on MLSS?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business". Milestone Scientific highlighted progress in building a scalable growth platform for its CompuFlo® medical business, noting momentum driven by expanding physician adoption, improved reimbursement access, broader commercial coverage, and growing clinical evidence.

Company

About Milestone Scientific, Inc.

Milestone Scientific Inc. is a biomedical technology company focused on developing and commercializing computer-controlled injection systems for medical and dental use. The company’s product portfolio includes technologies designed to improve the precision, consistency, and comfort of local anesthetic delivery in clinical settings. Its offerings are used across dental procedures and selected medical applications, supporting providers who rely on controlled drug delivery and injection accuracy. Milestone Scientific operates through dental and medical business segments, with products such as The Wand, STA systems, CompuDent, and CompuFlo forming the core of its commercial activity. The company serves healthcare professionals and institutions that use advanced injection technology in everyday patient care. Headquartered in Roseland, New Jersey, Milestone Scientific occupies a niche role in the medical devices market by combining research, patents, and product development around injection instrumentation.

CEO Mr. Eric C. Hines · 15 employees · United States · https://www.milestonescientific.com